APA (7th ed.) Citation

Weisel, K., Ludwig, H., Rieth, A., Lebioda, A., & Goldschmidt, H. (2020). Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data. Quality of life research, 29(1), . https://doi.org/10.1007/s11136-019-02307-5

Chicago Style (17th ed.) Citation

Weisel, Katja, Heinz Ludwig, Achim Rieth, Andrea Lebioda, and Hartmut Goldschmidt. "Health-related Quality of Life of Carfilzomib- and Daratumumab-based Therapies in Patients with Relapsed/refractory Multiple Myeloma, Based on German Benefit Assessment Data." Quality of Life Research 29, no. 1 (2020). https://doi.org/10.1007/s11136-019-02307-5.

MLA (9th ed.) Citation

Weisel, Katja, et al. "Health-related Quality of Life of Carfilzomib- and Daratumumab-based Therapies in Patients with Relapsed/refractory Multiple Myeloma, Based on German Benefit Assessment Data." Quality of Life Research, vol. 29, no. 1, 2020, https://doi.org/10.1007/s11136-019-02307-5.